Home/Context Therapeutics/Jennifer Dashnau, PhD, MBA
JD

Jennifer Dashnau, PhD, MBA

SVP Technical Operations

Context Therapeutics

Therapeutic Areas

Context Therapeutics Pipeline

DrugIndicationPhase
CTIM-76Solid tumors expressing Claudin 6 (CLDN6)Phase 1
CT-95Advanced solid tumors expressing Mesothelin (MSLN)Phase 1
CT-202Solid tumors expressing Nectin-4Phase 1